ArticlePloS one2015
Molecular Profiling of a Rare Rosette-Forming Glioneuronal Tumor Arising in the Spinal Cord.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- The Clinical and Molecular Landscape of Rosette-Forming Glioneuronal Tumors.Biomedicines · 2024Review
- Other Less Prevalent Tumors of the Central Nervous System.Advances in experimental medicine and biology · 2023Article
- Molecular analyses of rosette-forming glioneuronal tumor of the midbrain tegmentum: A report of two cases and a review of the FGFR1 status in unusual tumor locations.Surgical neurology international · 2022Article
- Spinal rosette-forming glioneuronal tumor: First case in a young child.Radiology case reports · 2021Article
- Rosette-Forming Glioneuronal Tumor of the Fourth Ventricle: A Case of Relapse Treated with Proton Beam Therapy.Diagnostics (Basel, Switzerland) · 2021Article
- Surgical treatment of a rare rosette-forming glioneuronal tumor in the pineal region.Surgical neurology international · 2020Article
- Supratentorial intraventricular rosette-forming glioneuronal tumors - Case report and review of treatment paradigms.Surgical neurology international · 2020Article
- Spinal rosette-forming glioneuronal tumor: A case report.Medicine · 2019Article
- Anaplastic glioneuronal tumor withIntractable & rare diseases research · 2019Article
- Rosette-forming glioneuronal tumour of dorsolumbar spinal cord.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2019Article
- Malignant Transformation of a Rosette-Forming Glioneuronal Tumor with IDH1 Mutation: A Case Report and Literature Review.World neurosurgery: X · 2019Article
- Comprehensive genetic characterization of rosette-forming glioneuronal tumors: independent component analysis by tissue microdissection.Brain pathology (Zurich, Switzerland) · 2018Article
- Histopathological, molecular, clinical and radiological characterization of rosette-forming glioneuronal tumor in the central nervous system.Oncotarget · 2017Article
- Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.Cold Spring Harbor molecular case studies · 2016Article
- Copy Number Profiling of Brazilian Astrocytomas.G3 (Bethesda, Md.) · 2016Article
- Rosette-forming glioneuronal tumor: an illustrative case and a systematic review.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 4 countries.
Funding
Abstract
Rosette-forming glioneuronal tumor (RGNT) of the IV ventricle is a rare and recently recognized brain tumor entity. It is histologically composed by two distinct features: a glial component, resembling pilocytic astrocytoma, and a component forming neurocytic rosettes and/or perivascular rosettes. Herein, we describe a 33-year-old man with RGNT arising in the spinal cord. Following an immunohistochemistry validation, we further performed an extensive genomic analysis, using array-CGH (aCGH), whole exome and cancer-related hotspot sequencing, in order to better understand its underlying biology. We observed the loss of 1p and gain of 1q, as well as gain of the whole chromosomes 7, 9 and 16. Local amplifications in 9q34.2 and 19p13.3 (encompassing the gene SBNO2) were identified. Moreover, we observed focal gains/losses in several chromosomes. Additionally, on chromosome 7, we identified the presence of the KIAA1549:BRAF gene fusion, which was further validated by RT-PCR and FISH. Across all mutational analyses, we detected and validated the somatic mutations of the genes MLL2, CNNM3, PCDHGC4 and SCN1A. Our comprehensive molecular profiling of this RGNT suggests that MAPK pathway and methylome changes, driven by KIAA1549:BRAF fusion and MLL2 mutation, respectively, could be associated with the development of this rare tumor entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.